4.7 Article

Evaluation of Clonality and Carbapenem Resistance Mechanisms among Acinetobacter baumannii-Acinetobacter calcoaceticus Complex and Enterobacteriaceae Isolates Collected in European and Mediterranean Countries and Detection of Two Novel β-Lactamases, GES-22 and VIM-35

Journal

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 58, Issue 12, Pages 7358-7366

Publisher

AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.03930-14

Keywords

-

Funding

  1. Janssen Research Development
  2. American Proficiency Institute
  3. Anacor
  4. Astellas
  5. AstraZeneca
  6. Bayer
  7. Cempra
  8. Cerexa
  9. Cosmo Technologies
  10. Contrafect
  11. Cubist
  12. Daiichi
  13. Dipexium
  14. Enanta
  15. Furiex
  16. GlaxoSmithKline
  17. Johnson Johnson
  18. LegoChem Biosciences Inc.
  19. Meiji Seika Kaisha
  20. Merck
  21. Nabriva
  22. Novartis
  23. Pfizer (Wyeth)
  24. PPD Therapeutics
  25. Rempex
  26. Melinta (Rib-X) Pharmaceuticals
  27. Seachaid
  28. Shionogi
  29. Medicines Co.
  30. Theravance
  31. ThermoFisher
  32. Vertex Pharmaceuticals

Ask authors/readers for more resources

We evaluated doripenem-resistant Acinetobacter baumannii-Acinetobacter calcoaceticus complex (ACB; n = 411) and Enterobacteriaceae (n = 92) isolates collected from patients from 14 European and Mediterranean countries during 2009 to 2011 for the presence of carbapenemase-encoding genes and clonality. Following susceptibility testing, carbapenem-resistant (doripenem MIC, >2 mu g/ml) isolates were screened for carbapenemases. New beta-lactamase genes were expressed in a common background and susceptibility was tested. Class 1 integrons were sequenced. Clonality was evaluated by pulsed-field gel electrophoresis and multilocus sequence typing (Pasteur scheme). Relative expression of beta-lactam intrinsic resistance mechanisms was determined for carbapenemase-negative Enterobacteriaceae. ACB and Enterobacteriaceae displayed 58.9 and 0.9% doripenem resistance, respectively. bla(OXA-23), bla(OXA-58), and bla(OXA-24/OXA-40) were detected among 277, 77, and 29 ACB, respectively (in 8, 6, and 5 countries). Ten Turkish isolates carried bla(GES-11) or bla(GES-22). GES-22 (G243A and M169L mutations in GES-1) had an extended-spectrum beta-lactamase profile. A total of 33 clusters of >= 2 ACB isolates were observed, and 227 isolates belonged to sequence type 2/international clone II. Other international clones were limited to Turkey and Israel. Doripenem-resistant Enterobacteriaceae increased significantly (0.7 to 1.6%), and 15 bla(KPC-2)-and 22 bla(KPC-3)-carrying isolates, mostly belonging to clonal complexes 11 and 258, were observed. Enterobacteriaceae isolates producing OXA-48 (n = 16; in Turkey and Italy), VIM-1 (n = 10; in Greece, Poland, and Spain), VIM-26 (n = 1; in Greece), and IMP-19, VIM-4, and the novel VIM-35 (n = 1 each from Poland) were detected. VIM-35 had one substitution compared to VIM-1 (A235T) and a similar susceptibility profile. One or more resistance mechanisms were identified in 4/6 carbapenemase-negative Enterobacteriaceae. This broad evaluation confirms results from country-specific surveys and shows a highly diverse population of carbapenemase-producing ACB and Enterobacteriaceae in Europe and Mediterranean countries.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available